Acute myeloid leukemia research hub

ABT-199 (Venetoclax) and Purine analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (ApoAML)

This study looks at new drug combinations for adults with Acute Myeloid Leukaemia (AML) that has come back or not responded to previous treatment. It tests venetoclax and mercaptopurine together to see how well they work and if they are safe.

A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

This study looks at a new combination treatment for acute myeloid leukaemia (AML) in people who can't have strong chemotherapy. It compares a drug called Venetoclax plus a low-dose chemotherapy called Cytarabine, to just low-dose Cytarabine on its own, to see which is more effective.

A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy

This study is looking at a new combination treatment for acute myeloid leukaemia (AML) in people who can't have strong chemotherapy. It combines two drugs, cusatuzumab and azacitidine, to see how well they help improve the patient's condition.

A Randomized, Double-blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy, Incorporating Extension Period - Continued Access for Venetoclax. (VIALE-A)

This study looks at a new treatment called venetoclax combined with an existing medicine called azacitidine for people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It aims to see if this combination works better than azacitidine alone for patients who can't have standard strong chemotherapy.

Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML).

This study is looking at a new combination treatment for acute myeloid leukemia (AML), a type of blood cancer. It combines a new drug, Liposomal Annamycin, with a standard treatment, cytarabine. Researchers want to see if this new combination is safe and effective.

An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refractory Acute Myeloid Leukemia and in Combination with 5-Azacytidine and Venetoclax for Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Negative for NPM1 and IDH 1/2 Mutations Who Are Ineligible for Intensive Chemotherapy (AARON)

This study looks at new drug combinations for acute myeloid leukaemia (AML). It aims to find the safest dose and see how well these combinations work in people whose AML has come back or not responded to treatment, and in newly diagnosed patients who can't have strong chemotherapy.

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in adults who can't have strong chemotherapy. It compares a drug combination of three medicines (pevonedistat, venetoclax, and azacitidine) against a two-drug combination (venetoclax and azacitidine) to see which works best.

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination with Standard of Care Therapy in Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia (BEXMAB Study)

This study is testing a new drug called bexmarilimab for blood cancers like MDS, CMML, and AML. It aims to see if the drug is safe, what dose is best, and if it helps people get better when used with standard treatments.

Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial

This study looks at new, personalised treatments for older people with certain blood cancers like Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). It compares these 'precision' treatments with standard care to see which works best and offers the best value for money in improving quality of life.

MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse (PEMAZA)

This study looks at a new way to treat acute myeloid leukaemia (AML) in adults. It's for people whose AML might be coming back. We're testing a combination of two medicines, pembrolizumab and azacitidine, to see if it can keep the cancer away for longer.

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

This study is testing new ways to treat certain blood cancers, like some types of leukaemia and myelodysplastic syndromes. Researchers are looking at a new drug, ASTX030, sometimes with another drug called venetoclax, to see if it's safe and works better than current treatments.

GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia

This study, called GRACE, is for adults (16-55) with a difficult-to-treat blood cancer called AML. It tests a new transplant method using umbilical cord blood and special white blood cells (granulocytes) to see if it's safer and more effective than current treatments.

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

This study looks at a new drug, bexmarilimab, alongside standard treatments for certain blood cancers like leukaemia and MDS. We want to find a safe dose and see how well it works to help patients.

A Study of BGB-11417 in Participants With Myeloid Malignancies

This study is looking at a new drug, BGB-11417, for certain blood cancers like acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Researchers want to see if it's safe, what dose works best, and if it helps people, either alone or with another treatment called azacitidine.

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

This study is looking at a new drug called bleximenib in people with a type of blood cancer called acute leukaemia. Researchers want to understand how the body handles this drug.

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

This study looks at restoring healthy gut bacteria in people with blood cancers before a stem cell transplant. We're testing special capsules (IMT) against a dummy capsule to see if they improve gut health and reduce common problems like infections after transplant.

Study to Evaluate the Safety and Tolerability of EP0042

This study is looking at a new treatment called EP0042 for advanced blood cancers like acute myeloid leukaemia (AML). It aims to find a safe and effective dose of EP0042, sometimes combined with other medicines, for patients whose cancer treatments haven't worked or have stopped working.

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

This study is looking at a medicine called ponatinib for children aged 1 to 17 with certain types of cancer, like leukemia and lymphoma. We want to see how safe it is and how well it works when other treatments haven't helped or aren't suitable.

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

This study is testing a new drug, IMGN632, for adults with a type of blood cancer called Acute Myeloid Leukemia (AML). It's looking at whether IMGN632 is safe and effective when given alone or with other common AML treatments.

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

This study looks at a new way to treat a specific type of leukaemia (AML) with a gene change called IDH1. It adds a drug called venetoclax to standard treatment (ivosidenib and azacitidine) to see if it works better. It's for patients who can't have strong chemotherapy.

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.

An international, multicenter, randomized, double-blind, phase 3 pivotal registrational clinical study of APG-2575 (Lisaftoclax) combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (GLORA-3)

This study is testing a new drug, Lisaftoclax, alongside a standard treatment (azacitidine) for older patients with newly diagnosed acute myeloid leukemia (a type of blood cancer). It aims to see if adding Lisaftoclax helps people live longer and improves other aspects of their health.

Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)

This study is testing a new drug called Revumenib with standard chemotherapy for children and young people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It's for those whose cancer has returned after treatment or hasn't responded to initial therapy.

A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy

This study is for older adults, or those unable to have standard chemotherapy, with newly diagnosed acute myeloid leukaemia. It tests two new medicines, Tibsovo and Inaqovi, taken as tablets, to see if they are safe and effective at treating the cancer.

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).

This study is testing a new medicine, Pivekimab Sunirine, in children and teenagers with a type of blood cancer called Acute Myeloid Leukaemia (AML) that has come back or hasn't responded to other treatments. The main aim is to see if the medicine is safe and how it moves through the body.

A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone

This study looks at a new drug, Tambiciclib, given with standard leukaemia treatments (Venetoclax and Azacitidine). It's for adults with acute myeloid leukaemia (AML) whose first two cycles of standard treatment didn't work well enough. Researchers want to see if adding Tambiciclib improves how many patients respond to treatment.

Methods of T Cell Depletion Trial (MoTD)

This study compares different ways to prevent a complication called GvHD after stem cell transplants for various blood cancers. It's looking for the best treatment plan to help patients recover well, using common medicines like Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.

An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL)

Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia